98%
921
2 minutes
20
The magnetic properties and safety of dextran-coated superparamagnetic iron oxide nanoparticles (SPIONs) have facilitated their clinical use as MRI contrast agents and stimulated research on applications for SPIONs in particle imaging and magnetic hyperthermia. The wider clinical potential of SPIONs, however, has been limited by their rapid removal from circulation via the reticuloendothelial system (RES). We explored the possibility of extending SPION circulatory time using fucoidan, a seaweed-derived food supplement, to inhibit RES uptake. The effects of fucoidan on SPION biodistribution were evaluated using ferucarbotran, which in its pharmaceutical formulation (Resovist) targets the RES. Ferucarbotran was radiolabeled at the iron oxide core with technetium-99m (Tc; t = 6 h) or zirconium-89 (Zr; t = 3.3 days). Results obtained with Tc-ferucarbotran demonstrated that administration of fucoidan led to a 4-fold increase in the circulatory half-life (t slow) from 37.4 to 150 min (n = 4; P < 0.0001). To investigate whether a longer circulatory half-life could lead to concomitant increased tumor uptake, the effects of fucoidan were tested with Zr-ferucarbotran in mice bearing syngeneic subcutaneous (GL261) tumors. In this model, the longer circulatory half-life achieved with fucoidan was associated with a doubling in tumor SPION uptake (n = 5; P < 0.001). Fucoidan was also effective in significantly increasing the circulatory half-life of perimag-COOH, a commercially available SPION with a larger hydrodynamic size (130 nm) than ferucarbotran (65 nm). These findings indicate successful diversion of SPIONs away from the hepatic RES and show realistic potential for future clinical applications.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acsnano.7b06734 | DOI Listing |
J Control Release
September 2025
Research Department of Imaging Chemistry and Biology, School of Biomedical Engineering & Imaging Sciences, King's College London, London, United Kingdom. Electronic address:
The blood-brain barrier (BBB) significantly hinders the treatment of central nervous system (CNS) disorders and brain tumors with intact BBB by restricting the entry of most therapeutic agents, including small-molecule drugs and particularly larger macromolecules. Liposomal formulations, such as PEGylated liposomes with long blood half-lives, high drug-carrying capacity, and reduced off-site toxicity, can be useful for brain drug delivery, but their large size often limits BBB penetration. A novel liposomal doxorubicin formulation(Talidox®) with a smaller size (~36 nm, determined by TEM), increased blood circulation half-life (median reported half-life 96 h), and better stability than previous clinical formulations, can be a suitable choice for brain delivery.
View Article and Find Full Text PDFJ Med Chem
September 2025
Gansu Provincial Key Laboratory of Environmental Oncology, Department of Tumor Center, Lanzhou University Second Hospital, Second Clinical Medical School, Lanzhou University, Lanzhou 730000, China.
Antibody-drug conjugates (ADCs) represent a promising class of cancer therapeutics. This innovative molecular design perfectly integrates the targeting and extended half-life of antibodies with the cytotoxicity of small molecules, enabling the selective delivery of payloads to cancer cells. The linker molecule is crucial to the efficacy of an ADC.
View Article and Find Full Text PDFClin Pharmacol Drug Dev
August 2025
Longboard Pharmaceuticals (now a part of Lundbeck LLC), La Jolla, CA, USA.
Bexicaserin (LP352) is a selective 5-hydroxytryptamine 2C (5-HT) superagonist in development for the treatment of seizures in developmental and epileptic encephalopathies (DEEs). This double-blind, placebo-controlled, single ascending dose (SAD) Phase 1 study aimed to assess the safety, tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single oral doses of bexicaserin and determine any relevant food effects. Forty healthy adult females were randomized to six treatment groups (1, 3, 6, 12, and 24 mg fasted; 6 mg fed) or placebo.
View Article and Find Full Text PDFPharmaceuticals (Basel)
August 2025
College of Pharmaceutical Science, Zhejiang University, No. 866 Yuhangtang Road, Hangzhou 310058, China.
Staphylococcus aureus () is a clinically significant pathogenic bacterium. Daptomycin (DAP) is a cyclic lipopeptide antibiotic used to treat infections caused by multidrug-resistant Gram-positive bacteria, including . However, DAP currently faces clinical limitations due to its short half-life, toxic side effects, and increasingly severe drug resistance issues.
View Article and Find Full Text PDFBiomater Adv
August 2025
Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India. Electronic address:
Cancer remains one of the most challenging diseases for targeted drug delivery despite the advancements in conventional as well as cutting-edge treatments. In recent years, rapid progress has been made in the field of nanomedicine, offering novel strategies, holding the potential to transform healthcare by enhancing bioavailability, efficacy and safety. Notably, the targeting ability of these nanotherapeutic drug delivery systems has been refined by tailoring nanoscale properties and modified surface features, furnishing an alternative approach to tumour-targeted therapy.
View Article and Find Full Text PDF